KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
(NASDAQ:KALA), — Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 — — Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 — ARLINGTON, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) — […]